IDNA
iShares Genomics Immunology and Healthcare ETF
IDNA seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 156.3 M
ASSETS UNDER MGMT
47 bp
EXPENSES
Fund Basics
| Inception date | Jun 11, 2019 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| REVOLUTION MEDICINES, INC. | 7.4 % |
| MODERNA, INC. | 6.4 % |
| IPSEN | 4.8 % |
| MERCK & CO. INC. | 4.4 % |
| TWIST BIOSCIENCE CORP. | 4.3 % |
| EXELIXIS INC | 4.2 % |
| TAKEDA PHARMACEUTICAL CO LTD | 4.2 % |
| BAYER AG | 4.1 % |
| ROCHE PS PAR AG | 4.0 % |
| GSK PLC | 3.9 % |
Constituent Breakdown
| Number of holdings | 52 |
| Herfindahl-Hirschman Index | 375 |
| Wgt avg mkt cap (mns) | $50,607 |
| Large cap (>$10bn) | 64.0% |
| Mid cap ($2-10bn) | 12.8% |
| Small cap (<$2bn) | 16.2% |
| Developed mkts. | 90.8% |
| Emerging mkts. | 0.5% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 56.0 % |
 |
FRANCE | 8.7 % |
 |
GERMANY | 7.8 % |
 |
JAPAN | 6.2 % |
 |
BRITAIN | 3.9 % |
 |
DENMARK | 3.1 % |
 |
SWITZERLAND | 1.9 % |
 |
CANADA | 1.6 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 14.1% | 47.7% | 12.3% | 7.8% | -8.6% | -- | -- | 2.6% |
| Dividend Yield | 0.0% | 2.0% | 1.3% | 1.2% | 0.8% | -- | -- | 0.8% |
| Total Returns | 14.1% | 49.7% | 13.5% | 9.0% | -7.8% | -- | -- | 3.5% | Ann. Volatility | 26.4% | 24.4% | 24.7% | 24.8% | 28.4% | -- | -- | 29.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.16 | 31% |
| MSCI EAFE | 1.02 | 39% |
| MSCI Emg Mkts | 0.67 | 29% |
Liquidity Measures
| Avg. volume (000) | 45 |
| ADV traded (mns) | $1 |
| Turnover | 0.8% |
| Avg. Bid/Ask (% of price) | 0.29% |
Technical Indicators
| 30d moving avg. (EMA) | $29.60 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 0.01/-0.07 |
| Bollinger Bands (Upper/Lower) | $30.53/$28.55 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. IDNA |
Expenses vs. IDNA |
ALTAR Score™ vs. IDNA |
|---|---|---|---|---|
| CANC | Tema Oncology ETF | 21.0% | +28 bp | -0.4% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 21.0% | -12 bp | -2.6% |
| BBP | Virtus LifeSci Biotech Products ETF | 19.7% | +32 bp | -2.3% |
| GNOM | Global X Genomics & Biotechnology ETF | 19.0% | +3 bp | -1.4% |
| BBH | VanEck Biotech ETF | 19.0% | -12 bp | +6.4% |
| WDNA | WisdomTree BioRevolution Fund | 18.4% | -2 bp | -1.4% |
| IBB | iShares Biotechnology ETF | 17.2% | -2 bp | +1.0% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 16.5% | +13 bp | +9.4% |
| XBI | State Street SPDR S&P Biotech ETF | 16.0% | -12 bp | +1.6% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 15.0% | +9 bp | +3.6% |
Risk and Returns: IDNA vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/3/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.6%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 727 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. IDNA's ALTAR Score™ is approximately -2.3 standard
deviations above the category average. This places IDNA in the 1st percentile
among funds in the category.
Sell-Side Consensus
$34.56
PRICE TARGET
+20.5%
UPSIDE